Articles tagged with Tumor Microenvironments
Long non-coding RNAs (lncRNAs) play a crucial role in regulating the tumor microenvironment, influencing processes such as immune evasion, angiogenesis, and metastasis. They mediate interactions between tumor cells and their surrounding microenvironment, modulating stromal cell activities and promoting tumor growth and survival.
Researchers discovered that lipid accumulation promotes immune suppression and therapy resistance in triple negative breast cancer. Blocking Omega-6 fatty acid intake reversed treatment resistance. Disrupting lipid droplet formation also resensitized tumors to chemotherapy and immunotherapy.
Recent research highlights the crucial role of circadian rhythms in tumor biology, demonstrating their contribution to tumorigenesis, progression, and metastasis. Disruptions in these rhythms also influence the tumor immune microenvironment and the efficacy of anticancer therapies.
Researchers identified four distinct cell populations in PDAC, including MMP1+ and S100A2+ tumor cells, CCL2+ macrophages, and OMD+ fibroblasts. These cell subsets contribute to a pro-tumor microenvironment, predicting unfavorable prognosis.
A recent study has identified that the neuronal subtype responds best to immunotherapy, while other subtypes exhibit lower response rates. The researchers developed a machine-learning algorithm using large public data sets to predict treatment response based on tumor mutational burden and immune cell infiltration.
A study found that MAGE-4 drives the accumulation of plasma immune cells suppressing antitumor immunity in mouse and human non-small cell lung cancer models. The protein promotes tumor progression by losing a tumor suppressor gene, PTEN, accelerating development into metastasis.
Researchers discover mitochondrial transfer between cancer cells and immune cells as a key immune evasion strategy. Cancer cells can reshape the tumor microenvironment to weaken tumor-infiltrating lymphocytes, and mitochondria play a significant role in this process.
The Micro Immune Response On chip (MIRO) replicates tumours and their environment, allowing researchers to study the efficacy of immunotherapy treatments. This technology has been tested with breast cancer samples and shows promise in understanding how the immune system interacts with tumours.
The study analyzed 63 tumor samples from 10 common malignancies, revealing how malignant cells specialize in growing tumors and non-cancer cells contribute to the immune system's suppression. The findings suggest a hierarchical structure of tumors with specific hallmark expression patterns.
Concordia researchers propose a novel method using ultrasound-guided microbubbles to stimulate critical cytokine secretion in T cells, potentially re-activating them and increasing the release of proteins needed to fight cancer. The approach could complement existing treatments and improve outcomes.
A new study found that inhibiting TBK1 increases CAR-T cell activity and makes cancer cells more susceptible to immune cell targeting. The researchers used patient-derived organotypic tumor spheroids (PDOTS) models to investigate the mechanisms of treatment resistance in solid tumors.
HCC-derived exosomes reprogram immune and stromal cells to create an environment conducive to tumor growth. Exosome engineering holds promise for targeted therapies that enhance the efficacy of existing treatments.
Researchers found that treating the Golgi apparatus with hydrogen sulfide creates T-cells that can take more stress, leading to a better chance of controlling tumors. The study suggests sorting T-cells into high and low Golgi groups could be a new therapeutic target.
The conference explores molecular determinants of cancer therapy resistance, a major challenge in the fight against cancer. Researchers discuss new therapeutic approaches and address resistance mechanisms involving tumour cells and the tumour microenvironment.
Researchers at Anglia Ruskin University are investigating the complex relationship between fat tissue and colorectal cancer. The study aims to enhance knowledge of the tumour microenvironment, uncover new molecules crucial for cancer growth, and develop more effective treatments.
Researchers have developed an immunotherapy that targets glioblastoma by turning its microenvironment against it. The treatment uses CAR T-cells with a blueprint for a molecule that blocks tumor signals, allowing macrophages and microglia to support the attack on cancer cells.
Researchers developed a single-cell RNA-sequencing atlas of the Multiple Myeloma immune microenvironment across disease stages. The atlas reveals potential resistance mechanisms and identifies conventional dendritic cells as a targetable population in MM.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
Researchers at the University of Pittsburgh found that blocking the uptake of lactic acid, a key factor in T cell exhaustion, can reinvigorate these cells. This new approach shows promise for improving tumor control and treatment outcomes in various cancers.
Researchers at Michigan Medicine found that SLC13A3 transporter impairs tumor immunity by endowing ferroptosis resistance. This discovery suggests a potential target for improving immunotherapy responses in cancer patients.
Research highlights the role of gut dysbiosis in pancreatic ductal adenocarcinoma (PDAC), with specific microbial profiles associated with PDAC. Fecal microbiota transplantation (FMT) is proposed as a potential adjunct therapy to improve patient outcomes through microbiome modulation and immune system recalibration.
A new method to construct protein complex-based therapeutics has been discovered using a polymer cloak, which stabilizes the delivery of protein complexes and enables tumor-targeted immunomodulation. The study presents an IL-15 nanosuperagonist with enhanced efficacy and specificity, promising a safer therapy for cancer treatment.
Researchers have identified a 'forcefield-like' defense system in solid tumors, which uses small extracellular vesicles to block nanoparticle-based therapies. The study found that tumor cells release sEVs carrying proteins that block the activity of cytotoxic T cells and intercept nanoparticles like a decoy.
A new study by the University of Eastern Finland found that pro-inflammatory macrophages can transform prostate cancer cells into stem-like cells, making them resistant to treatment. The study reveals that these immune cells secrete factors that increase the expression of stem cell markers in prostate cancer cells.
Researchers highlight key phagocytosis checkpoints and 'do not eat me' signals as potential therapeutic targets for novel immunotherapies. The editorial summarizes challenges in targeting CD47 and potential solutions to overcome these obstacles.
Researchers have successfully visualized and tracked specific cells in deep brain tissue, including along the corpus callosum's nerve fibre highway. This advancement could potentially lead to better diagnostic tools for glioblastoma, a deadly brain cancer.
Researchers have developed a novel nanoparticle drug-delivery system to activate an immune pathway in combination with tumor-targeting agents, showing promising results in treating pancreatic cancer. Eight out of nine mice tested experienced tumor improvements, including two complete responses.
A new study finds that combining an inhibitor of a metabolic pathway with chemotherapy could improve treatment outcomes in triple negative breast cancer brain metastases. Inhibiting fatty acid synthase, an enzyme critical for cancer cell survival, shows promise in improving chemotherapy efficacy.
Researchers explore non-invasive physical stimulation to alter tumor vasculature, extracellular matrix, and immune responses, enhancing cancer treatment efficacy. This approach breaks physical barrier limitations of the tumor microenvironment, optimizing existing protocols.
Researchers at Karolinska Institutet developed nanorobots that target and kill cancer cells using a 'kill switch' activated in low pH environments. The study achieved a 70% reduction in tumour growth in mice, paving the way for further investigation into its potential as a cancer treatment.
Researchers at The Jackson Laboratory discovered a cascade of molecules that help coordinate the attack of cytotoxic T-cells on tumors. Elevated levels of IL-3 reenergize these cells, signaling them to resume detecting and destroying tumors, with rare basophils playing a key role in this process.
Researchers found that tumor-associated macrophages respond to physical properties of fibrosis by synthesizing injury-associated collagens, resulting in metabolic changes that suppress CTL function. This provides an alternative explanation for why anti-tumor immunity is impaired in fibrotic solid tumors.
Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.
The study reviews various immunotherapies for HCC, including ICIs and cellular therapies, highlighting their potential in managing advanced disease and preventing recurrence. Emerging strategies like vaccine development and oncolytic virotherapy are also discussed.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
Researchers found a strong association between favorable survival outcomes and high populations of tissue-resident memory T cells in melanoma patients. The study identified 11 distinct gene signatures that correlate with T cell abundance and patient survival, suggesting a crucial role for T cells in immunomodulation.
Researchers discovered two distinct subtypes of hepatocellular carcinoma (HCC) and developed a risk score model predicting patient prognosis. The study identified potential drugs associated with prognostic genes, providing a novel model for HCC treatment.
A new study developed two machine learning models to quantify CD8+ cell positivity and classify the immunophenotype of cancer specimens in patients with non-small cell lung cancer. The models hold promise for identifying patients who may benefit from immunotherapy.
New findings in The American Journal of Pathology indicate that periostin promotes esophageal squamous cell carcinoma progression by enhancing cancer and stromal cell migration in cancer-associated fibroblasts. Periostin may be a promising therapeutic target for treating ESCC.
Researchers unveil innovative strategies to overcome metabolic constraints in CAR-T cell therapy, aiming to boost its efficacy in treating solid tumors. Metabolic interventions targeting immunosuppressive metabolites, metabolite uptake, and mitochondrial metabolism are proposed to enhance anti-tumor activity.
A team of researchers from Kyoto University has developed a microfluidic co-culture vasculature chip that mimics the microenvironment of alveolar soft part sarcoma (ASPS), a rare cancer. The chip enables scientists to study cell-to-cell interactions and angiogenic mechanisms, which may lead to new strategies for treating ASPS patients.
A study published in Nature found that the response to hematopoietic insults differs across the skeleton, with certain bones specialized to respond to specific stresses. The research uses confocal imaging microscopy to count different cell types and provides new insights into blood cell production, potentially leading to improved treat...
This study proposes the concept of early explosive recurrence (EER) in HCC patients, characterized by rapid intrahepatic dissemination and poor prognosis. EER is associated with distinct immune profiles and treatment responses.
Researchers define a 'core senescent profile' in human colon fibroblasts, revealing potential driver proteins involved in CRC. The study's findings provide insights into therapies for improving overall health and preventing CRC.
A new model of glioblastoma's key feature, oncostreams, could help scientists understand how to develop new treatments for this aggressive brain cancer. The model, developed by a team at the University of Michigan, identifies a potential inhibitor that appears to dismantle oncostreams, leading to better survival in mouse models.
Researchers developed an oxidative stress-based prognostic model for bladder cancer, identifying distinct molecular subtypes and predicting patient outcomes. The model shows promise in tailoring personalized treatment approaches, particularly for patients with low-risk profiles.
A recent study by Pusan National University scientists discovered the crucial role of PKM gene and EPHA2 pathway in HNSCC development. The research highlights the importance of HPV infection status in shaping the tumor microenvironment, enabling precision medicine for targeted treatment.
A novel three-drug combination of an HDAC inhibitor with two types of immunotherapy achieved a 25% overall response rate and 50% progression-free survival in women with advanced HER2-negative breast cancer. Patients with triple-negative breast cancer had a higher response rate, highlighting the need for further clinical evaluation.
Lung adenocarcinoma cells manipulate macrophage lipid metabolism to drive tumor progression. This exploitation of immune cells' metabolic pathways may be targeted with statins, improving lung cancer treatments.
A novel reporter cell experimental system enables the visualization of sequential changes during endothelial-mesenchymal transition (EndoMT) induced by transforming growth factor-β. Researchers identified CD40 as a potential partial EndoMT marker, which suppresses the transition from partial to full EndoMT.
Researchers found that artepillin C interacts intensely with tumor cells, altering their fluidity and triggering autophagy. The study's results contribute to a deeper understanding of the substance's action mechanisms and provide insights for future research.
Researchers identified senescence-related tumor microenvironment genes associated with poor prognosis, genetic alterations, and reduced responsiveness to immunotherapy in HNSC. The study highlights the importance of precision medicine approaches for personalized treatment.
Researchers analyzed LTBR expression levels in various cancers, finding it associated with low patient survival and immune cell infiltration. The study identified LTBR as a potential target for cancer immunotherapy and marker of poor prognosis.
A groundbreaking study identifies FAM3C as a key regulator of breast cancer progression within the tumor microenvironment. The overexpression of FAM3C promotes breast cancer cell survival and metastasis, while its depletion inhibits tumor growth in genetically engineered mouse models.
Researchers developed a new imaging technique to visualize the tumor microenvironment of glioblastoma, revealing insights into its pathology. The technique uses PET imaging with Carbon-11 acetate, tracking reactive astrocytes and distinguishing them from tumor cells.
Cancer stem cell-derived exosomes (CSC-Exos) are essential for communication between CSCs and other cells in the tumor microenvironment, contributing to cancer progression. The editorial highlights their potential as a novel clinical tool for diagnosis, prognosis, prevention of tumor recurrence, and therapeutic strategy
The iStar tool uses advanced techniques to capture both detailed views of individual cells and broader tissue patterns, enabling doctors to diagnose cancers that might otherwise go undetected. It also predicts gene activities at near-single-cell resolution, paving the way for molecular disease diagnosis.
This review highlights the role of single-cell sequencing in HBV-HCC research, shedding light on tumor heterogeneity and immune microenvironment dynamics. The study provides new avenues for visualizing intratumoral and intertumoral heterogeneity, monitoring tumor progression, and preventing cellular deterioration.
A new study found that perivascular fibroblasts support the creation of an immunosuppressive tumor microenvironment, allowing glioblastoma to evade the immune system. The fibroblasts may also promote stem-like cancer cells that rarely divide, leading to poor survival outcomes.
Studies at single-cell resolution reveal significant tumor cell heterogeneity and an immune-evasive environment that contributes to treatment resistance in T follicular helper cell lymphomas. A novel marker, PLS3, is also identified as a key player in this process.